Journal article
Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials
Abstract
IMPORTANCE: Multiple effective first-line systemic treatment options are available for patients with advanced BRAF-mutated melanoma. A lack of head-to-head randomized clinical trials (RCTs) comparing targeted and immunotherapies leaves uncertainty regarding optimal first-line treatment.
OBJECTIVE: To estimate the relative efficacy and safety of systemic therapies for advanced, treatment-naive, BRAF-mutated melanoma.
Authors
Devji T; Levine O; Neupane B; Beyene J; Xie F
Journal
JAMA Oncology, Vol. 3, No. 3, pp. 366–373
Publisher
American Medical Association (AMA)
Publication Date
March 1, 2017
DOI
10.1001/jamaoncol.2016.4877
ISSN
2374-2437
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Antineoplastic Combined Chemotherapy ProtocolsCTLA-4 AntigenDisease-Free SurvivalHumansMelanomaMitogen-Activated Protein Kinase KinasesMolecular Targeted TherapyMutationProgrammed Cell Death 1 ReceptorProtein Kinase InhibitorsProto-Oncogene Proteins B-rafRandomized Controlled Trials as TopicSkin NeoplasmsSurvival AnalysisTreatment Outcome